Publications

Selected Publications:(Please note, the availability or otherwise of electronic reprints depends on your institution’s own licensing arrangements with the publishers. I cannot for copyright reasons email you pdf’s if you do not have electronic access to the journal concerned.

“Orally Absorbed Cyclic Peptides” Nielsen, D. S.; Shepherd, N. E.; Xu, W.; Lucke, A. J.; Stoermer, M. J.; Fairlie, D. P.  Chemical Reviews 2017. Full text via ACS publications.

Xray crystal structure of cyclosporine A, Dotted lines indicate internal hydrogen bonds. (Loosli 1985).

“Receptor residence time trumps drug-likeness and oral bioavailability in determining efficacy of complement C5a antagonists” Vernon Seow, Junxian Lim, Adam J. Cotterell, Mei-Kwan Yau, Weijun Xu, Rink-Jan Lohman, W. Mei Kok, Martin J. Stoermer, Matthew J. Sweet, Robert C. Reid, Jacky Y. Suen & David P. Fairlie.Scientific Reports, 2016, 24575.  doi:10.1038/srep24575 Full text via nature.com. Free via PubMed Central.

Comparative properties and in vitro potencies of C5aR antagonists. Reproduced with permission. Copyright © 2016, Rights Managed by Nature Publishing Group

“Simultaneous uncoupled expression and purification of the Dengue virus NS3 protease and NS2B co-factor domain” Ashleigh E. Shannon, Keith J. Chappell, Martin J. Stoermer, Shiao Y. Chow., Woan M. Kok, David P. Fairlie, Paul R. Young. Protein Expression and Purification, 2016, 119, 124–129. doi:10.1016/j.pep.2015.11.02. Full text via ScienceDirect

Reproduced with permission. Copyright © Elsevier 2016

“Virtual Screening of Peptide and Peptidomimetic Fragments Targeted to Inhibit Bacterial Dithiol Oxidase DsbA”  Wilko Duprez, Prabhakar Bachu, Martin J. Stoermer, Stephanie Tay, Róisín M. McMahon, David P. Fairlie, Jennifer L. Martin. PLoS ONE, 2015,  10(7): e0133805. doi:10.1371/journal.pone.0133805. Full text via plos.org.

Comparison of the docked designed peptidomimetic with the EcDsbA-EcDsbB and PmDsbA-PWATCDS crystal structures. Copyright: © 2015 Duprez et al. Reprinted with permission.

“Three Homology Models of PAR2 Derived from Different Templates: Application to Antagonist Discovery” Samuel R. Perry , Weijun Xu , Anna Wirija , Junxian Lim , Mei-Kwan Yau , Martin J. Stoermer , Andrew J. Lucke , and David P. Fairlie. J. Chem. Inf. Model., 2015, 55, 1181-1191. Full text via ACS Publications.

Reprinted with permission from “Three Homology Models of PAR2 Derived from Different Templates: Application to Antagonist Discovery” Samuel R. Perry , Weijun Xu , Anna Wirija , Junxian Lim , Mei-Kwan Yau , Martin J. Stoermer , Andrew J. Lucke , and David P. Fairlie. J. Chem. Inf. Model., 2015, 55, 1181-1191. Copyright (2015) American Chemical Society

“Potent Heterocyclic Ligands for Human Complement C3a Receptor” Reid RC, Yau MK, Singh R, Hamidon JK, Lim J, Stoermer MJ, Fairlie DP, J. Med. Chem., 2014, 57, 8459-8470, Abstract via Pubmed, Full text via ACS publications.

Reprinted with permission from “Potent Heterocyclic Ligands for Human Complement C3a Receptor” Reid RC, Yau MK, Singh R, Hamidon JK, Lim J, Stoermer MJ, Fairlie DP, J. Med. Chem., 2014, 57, 8459-8470″ Copyright (2014) American Chemical Society

“Cyclic Penta- and Hexa- Leucine Peptides Without N-Methylation Are Orally Absorbed” Timothy A Hill , Rink-Jan J Lohman , Huy Ngoc Hoang , Daniel S Nielsen , Conor CG Scully , Woan Mei Kok , Ligong Liu , Andrew J Lucke , Martin J Stoermer , Christina I Schroeder , Stephanie Chaousis , Barbara Colless , Paul Vincent Bernhardt , David J. Edmonds , David A. Griffith , Charles J. Rotter , Roger B. Ruggeri , David A. Price , Spiros Liras , David J Craik , and David P. Fairlie, ACS Med. Chem. Lett., 2014, 5, 1148-1151, Full Text via ACS Publications.

Reprinted with permission from “Cyclic Penta- and Hexa- Leucine Peptides Without N-Methylation Are Orally Absorbed” Timothy A Hill , Rink-Jan J Lohman , Huy Ngoc Hoang , Daniel S Nielsen , Conor CG Scully , Woan Mei Kok , Ligong Liu , Andrew J Lucke , Martin J Stoermer , Christina I Schroeder , Stephanie Chaousis , Barbara Colless , Paul Vincent Bernhardt , David J. Edmonds , David A. Griffith , Charles J. Rotter , Roger B. Ruggeri , David A. Price , Spiros Liras , David J Craik , and David P. Fairlie, ACS Med. Chem. Lett., 2014, 5, 1148-1151. Copyright (2014) American Chemical Society

“Downsizing a Human Inflammatory Protein to a Small Molecule with Equipotent Functions.” Robert C. Reid*, Mei-Kwan Yau, Ranee Singh, Johan K. Hamidon, Anthony N. Reed, Peifei Chu, Jacky Y. Suen, Martin J. Stoermer, Jade S. Blakeney, Junxian Lim, Jonathan M. Faber, David P. Fairlie*, Nature Commun., 2013, 4, 2802. Full text via Nature.com.

Modified by permission © 2013, Rights Managed by Nature Publishing Group

“Lithium  perchlorate  accelerated  Friedel-Crafts addition  of  furans to β-nitrostyrenes”       Martin J. Stoermer, Hans-Matthias Richter, Dieter E. Kaufmann, Tet. Lett. 2013, 54, 6776-6778. Full text via ScienceDirect.

Friedel-Crafts addition of furans to nitrostyrenes

“An interaction between the methyltransferase and RNA dependent RNA polymerase domains of the West Nile virus NS5 protein” Tan CS, Hobson-Peters JM, Stoermer MJ, Fairlie DP, Khromkyh AA, Hall RA, J. Gen. Virol., 2013, 94, 1961-1971. Abstract via Pubmed. Free Full text via J.Gen.Virol.

“Identification and characterization of bi-thiazole-2,2′-diamines as kinase inhibitory scaffolds” Kevin R Ngoei; Dominic C Ng; Paul R Gooley; David P Fairlie; Martin J Stoermer; Marie A. Bogoyevitch, Biochim. Biophys. Acta, Proteins Proteomics, 2013, 1834, 1077-88.Abstract via Pubmed. Full text via ScienceDirect.

“Identification of crotonyl glycine in urine of sheep after 48 h road transport” Juan Li, Horst Joachim Schirra, Yihua Yu, Michelle L. Colgrave, Martin J. Stoermer, Gene Wijffels, J. Pharmaceut. Biomed. Anal., 2012, 67-68, 129-36. Full text via ScienceDirect.

“Structures of peptide agonists for human protease activated receptor 2” Martin J. Stoermer, Bernadine Flanagan, Renée L. Beyer, Praveen K. Madala, David P. Fairlie, Biorg. Med. Chem. Lett., 2012, 22, 916-919. Full text via ScienceDirect.

“In silico screening of small molecule libraries using the dengue virus envelope E protein has identified compounds with antiviral activity against multiple flaviviruses” Thorsten Kampmann, Ragothaman Yennamalli, Phillipa Campbell, Martin J. Stoermer, David P. Fairlie, Bostjan Kobe, Paul R. Young Antiviral Research, 2009, 84(3), 234-41. Full text via ScienceDirect.

“Base-sensitivity of Arginine Alpha-Ketoamide Inhibitors of Serine Proteases.” Martin J. Stoermer, Donmienne Leung, Paul R. Young, David P. Fairlie, Aust. J. Chem, 2009, 62(9), 988-992. Full text via CSIRO publishing.

Alternative intramolecular cyclisation products of arginine α-ketoamide decomposition

 

“Structure of West Nile Virus NS3 Protease: Ligand Stabilization of Catalytic Conformation.” Gautier Robin, Keith Chappell, Martin J. Stoermer, Shu-Hong Hu, Paul R. Young, David P. Fairlie, Jennifer L Martin J. Mol. Biol. 2009, 385(5), 1568-1577. Full text via ScienceDirect.

Potent inhibitor 2-naphthoyl-KKR-aldehyde inhibitor bound to West Nile Virus NS2B/NS3 protease

“West Nile Virus NS2B/NS3 Protease as an Antiviral Target.” Keith J. Chappell, Martin J. Stoermer, David P. Fairlie, and Paul R. Young Curr. Med. Chem. , 2008, 15(27), 2771-2784 Abstract via Bentham ScienceFull text via IngentaConnect.

“Potent Cationic Inhibitors of West Nile Virus NS2B/NS3 Protease With Serum Stability, Cell Permeability and Antiviral Activity.” Martin J. Stoermer, Keith J. Chappell, Susann Liebscher, Christina M. Jensen, Chun H. Gan, Praveer K. Gupta, Wei-Jun Xu, Paul R. Young, and David P. Fairlie, J. Med. Chem. 2008, 51(18), 5714-5721. Full text via ACS publications

permissions statement

Reprinted with permission from “Potent Cationic Inhibitors of West Nile Virus NS2B/NS3 Protease With Serum Stability, Cell Permeability and Antiviral Activity.” Martin J. Stoermer, Keith J. Chappell, Susann Liebscher, Christina M. Jensen, Chun H. Gan, Praveer K. Gupta, Wei-Jun Xu, Paul R. Young, and David P. Fairlie, J. Med. Chem. 2008, 51(18), 5714-5721. Copyright (2008) American Chemical Society

 

” Synthesis and Cannabinoid Activity of a Variety of 2,3-Substituted 1-Benzo[b]thiophene Derivatives and 2,3-Substituted Benzofurans: Novel Agonists for the CB1 Receptor. ” Gerard P. Moloney, James A. Angus, Alan D. Robertson, Martin J. Stoermer, Michael Robinson, Lucy Lay, Christine E. Wright, Ken McRae and Arthur Christopoulos, Aust. J. Chem. 2008, 61(7), 484-499. Full Text via CSIRO Publishing.

“Synthesis and Cannabinoid Activity of 1-substituted-Indole-3-oxadiazole derivatives: Novel Agonists for the CB1 Receptor.” Gerard P. Moloney, James A. Angus, Alan D. Robertson, Martin J. Stoermer, Michael Robinson, Christine E. Wright, Ken McRae and Arthur Christopolous; Eur. J. Med. Chem., 2008, 43 (3), 513-539 Full Text via Sciencedirect

Oxadiazole-based CB1 selective agonist

“Mutagenesis of the West Nile virus NS2B cofactor domain reveals two regions essential for protease activity” Keith J. Chappell, Martin J. Stoermer, David P. Fairlie, and Paul R. Young J. Gen. Virol. , 2008, 89 (4), 1010-1014.Full Text via SGM Journals

“Generation and characterization of proteolytically active and highly stable truncated and full-length recombinant west nile virus NS3.” Keith J. Chappell, Martin J. Stoermer, David P. Fairlie, and Paul R. Young Protein Expr. Purif. , 2007, 3(1), 87-96 Full Text via Sciencedirect

“Insights to Substrate Binding and Processing by West Nile Virus NS3 Protease through Combined Modeling, Protease Mutagenesis, and Kinetic Studies.” Keith J. Chappell, Martin J. Stoermer, David P. Fairlie, and Paul R. Young J. Biol. Chem., 2006, 281(50), 38448-38458. Full Text via www.jbc.org

“Potencies of Human Immunodeficiency Virus Protease Inhibitors In Vitro against Plasmodium falciparum and In Vivo against Murine Malaria” Katherine T. Andrews, David P. Fairlie, Praveen K. Madala, John Ray, David M. Wyatt, Petrina M. Hilton, Lewis A. Melville, Lynette Beattie, Donald L. Gardiner, Robert C. Reid, Martin J. Stoermer, Tina Skinner-Adams, Colin Berry, and James S. McCarthy, Antimicrobial Agents And Chemotherapy, 2006, 50(2) 639-648. Full Text via aac.asm.org

“Current Status of Virtual Screening as Analysed by Target Class.” Martin J. Stoermer Medicinal Chemistry, 2006, 2(1), 89-112. Abstract via Bentham Science.

Growth in virtual screening publications and the size of the PDB database of protein structure 1990-2005

“Structural Mimicry of Two Cytochrome b562 Interhelical Loops Using Macrocycles Constrained By Oxazoles and Thiazoles.” Yogendra Singh, Martin J. Stoermer, Andrew J. Lucke, Tom Guthrie, David P. Fairlie. J. Am. Chem. Soc., 2005, 127(18), 6563-6572. Full Text via pubs.acs.org.

Reprinted with permission from “Structural Mimicry of Two Cytochrome b562 Interhelical Loops Using Macrocycles Constrained by Oxazoles and Thiazoles” Yogendra Singh, Martin J. Stoermer,Andrew J. Lucke,Tom Guthrie, and David P. Fairlie Journal of the American Chemical Society 2005 127 (18), 6563-6572. Copyright (2005) American Chemical Society.

“West Nile virus NS3 protease: Site-directed mutagenesis and kinetic studies that identify key enzyme-substrate interactions ” Keith J. Chappell, Tessa A. Nall, Martin J. Stoermer, Ning-Xia Fang, Joel D. A. Tyndall, David P. Fairlie, and Paul R. Young J. Biol. Chem., 2005, 280(4), 2896-2903. Full Text via www.jbc.org.

Figure 1 Reproduced with permission Copyright © 2005, by the American Society for Biochemistry and Molecular Biology

“Enzymatic characterisation and homology model of a catalytically active recombinant West Nile virus NS3 protease” T. A. Nall, K. J. Chappell, M. J. Stoermer, N. X. Fang, J. D. Tyndall, P. R. Young, and D. P. Fairlie, J. Biol. Chem., 2004, 279(47), 48535-48542. Full Text via www.jbc.org.

Interconverting aldehyde, hemiaminal, and hydrate forms of an inhibitor of WNV protease

“Potent Cyclic Antagonists Of The Complement C5a Receptor On Human Polymorphonuclear Leukocytes. Relationships Between Structures and Activity” Darren R. March, Lavinia M. Proctor, Martin J. Stoermer, Robert Sbaglia, Giovanni Abbenante, Robert C. Reid, Trent M. Woodruff, Khemar Wadi, Natalii Paczkowski, Joel D. A. Tyndall, Stephen M. Taylor, and David P. Fairlie. Mol. Pharmacology, 2004, 65, 868-879.
Full Text via Aspetjournals.

NMR solution structure of a C5a receptor ligand AcPhe[Orn-Pro-DPhe-Phe-Arg]

“Cycloadditions of Isobenzofuran to a Constrained Template Bearing Neighboring Dienophiles” Martin, J. Stoermer, Douglas N. Butler, Ronald N.Warrener, K. D. V. Weerasuria, and David P. Fairlie. Chem. Eur. J., 2003, 9(9), 2068-2071. [Full text via Wiley Interscience].

Cavitands formed by sequential Diels-Alder additions

“Regioselective Assembly of Antiparallel Loops on a Macrocyclic Scaffold Constrained by Oxazoles and Thiazoles” Yogendra Singh, Martin J. Stoermer, Andrew J. Lucke, Matthew P. Glenn and David P. Fairlie, Org. Lett., 2002, 4(20), 3367 – 3370. [Full text via ACS publications]

2 loop assembly on a macrocyclic oxazole/thiazole scaffold

“Compounds and Inhibitors Of Phospholipases”, Reid, Robert C.; Clark, Christopher I.; Hansford, Karl; Stoermer, Martin J.; McGeary, Ross P.; Fairlie, David P. PCT Int. Appl. (2002), WO 0208189.

potent sPLA2 inhibitor KH064

“Activity of recombinant dengue 2 virus NS3 protease in the presence of a truncated NS2B cofactor, small peptide substrates, and inhibitors”. Donmienne Leung, Kate Schroder, Helen White, Ning-Xia Fang, Martin J. Stoermer, Giovanni Abbenante, Paul R. Young, and David P. Fairlie, J. Biol. Chem., 2001, 276(49), 45762-45771. Full Text via www.jbc.org

Dengue NS2B/NS3 protease inhibitor AcFAAGRR-aldehyde

Australian Patent PR1180/00 “Therapeutic Molecules and Methods” Moloney, G. P., Robertson, A. D., Angus, J. A., Stoermer, M. J., Robinson, M., Lay, L., Wright, C., McRae, K., Christopolous, A., Coles. P. and Garavelas, A. 2000.

Australian Patent PQ8965/00 “Amino Acid Derivatives”, Clark, C., Hansford, K., Reid, R.C.,Stoermer, M.J., Fairlie, D.P., 2000

potent sPLA2 inhibitor KH064

“Chemistry in the Ambient Field of the Alkaloid Epibatidine, 1. 2-(Het)aryl-Substituted 7-Azabicyclo[2.2.1]heptane Systems”, Albert Otten, Jan Christoph Namyslo, Martin Stoermer, Dieter E. Kaufmann. Eur. J. Org. Chem. 1998, 1997-2001.[Full text via Wiley Interscience].

“Structure-Activity Relationships for Macrocyclic Peptido-Mimetic Inhibitors of HIV-1 Protease.” Abbenante, G., Bergman, D.A., Brinkworth, R.I., March, D.A., Reid, R.C., Hunt, P., James, I.W., Dancer, R.J., Garnham, B., Stoermer M.J., and Fairlie, D.P. Biorg. Med. Chem. Letters., 1996, 6, 2531.[Full text via ScienceDirect].

Macrocyclic HIV1-protease inhibitor

“1H n.m.r. Evidence for the Formation of Vinyllead Triacetates. The Reactions of Vinylmercury, Vinyltin, and Vinylboronic acids with Lead Tetraacetate”. C.J. Parkinson and Martin J. Stoermer, J. Organomet. Chem, 1996, 507, 207. [Full text via ScienceDirect].

Vinyllead triacetates and tribenzoates

“A Selective Route to Substituted Chromones. Addition of Phenols to Dimethyl Acetylenedicarboxylate.” M.J. Stoermer and D.P. Fairlie, Aust. J. Chem., 1995, 48(3), 677.[Full Text via CSIRO Publishing]

Synthetic Route to chrome-2-carboxylic acids

“Flavones are inhibitors of HIV-1 Proteinase”, R.I. Brinkworth, M.J. Stoermer, D.P. Fairlie, Biochem. Biophys. Res. Communications, 1992, 188(2), 631. Full Text via ScienceDirect.

“Electrophilic Vinylations by Vinyllead Triacetates and Tribenzoates Generated by Tin-Lead Exchange” Parkinson, C.J., Pinhey, J.T., and Stoermer, M.J., J. Chem. Soc. Perkin Trans. 1, 1992, 15, 1911. [ Full Text via RSC archive]

α-Vinylation of β-ketoesters with vinyllead triacetates

 

“Vinyl Cation Formation by Decomposition of Vinyllead(IV) Triacetates. Part 2”. Pinhey, J.T., and Stoermer, M.J., J. Chem. Soc. Perkin Trans. 1, 1991, 10, 2455. [ Full Text via RSC archive ]

Primary vinyl cation formation via decomposition of vinyllead triacetates

Vinyl Cation Formation by Decomposition of Vinyl-lead Triacetates. The reactions of Vinylmercury and Vinyltin Compounds with Lead Tetraacetate.” Moloney, M.G., Pinhey, J.T., and Stoermer, M.J., J. Chem. Soc. Perkin Trans. 1, 1990, 10, 2645. [ Full Text via RSC archive ]

Decomposition products of vinyl lead triacetates.

D J Chalmers, I T Crosby, A Garavelas, M Kiefel, and M J Stoermer. “Extracts”, Chemistry in Australia, January/February 1998, p37.

D J Chalmers, I T Crosby, A Garavelas, M Kiefel, and M J Stoermer. “Extracts”, Chemistry in Australia, August 1998, p24.

“Ethyl (E)-3-methyl-5-phenyl-2-pentenoate”, Martin J. Stoermer and John T. Pinhey, Molecules 1998, 3, M51.

“Ethyl (Z)-3-methyl-5-phenyl-2-pentenoate”, Martin J. Stoermer and John T. Pinhey, Molecules, 1998, 3, M52.

“(E)-3-Methyl-5-phenyl-2-pentenoic acid”, Martin J. Stoermer and John T. Pinhey, Molecules, 1998, 3, M53.

“(Z)-3-Methyl-5-phenyl-2-pentenoic acid”, Martin J. Stoermer and John T. Pinhey, Molecules, 1998, 3, M54.

“2(S,R),3(R,S)-2,3-Dibromo-3-methyl-5-phenyl-2-pentanoic acid”, Martin J. Stoermer and John T. Pinhey, Molecules, 1998, 3, M55.

“2(R,S),3(S,R)-2,3-Dibromo-3-methyl-5-phenyl-2-pentanoic acid”, Martin J. Stoermer and John T. Pinhey, Molecules, 1998, 3, M56.

“(Z)-1-Bromo-2-methyl-4-phenyl-1-butene”, Martin J. Stoermer and John T. Pinhey, Molecules, 1998, 3, M57.

“(E)-1-Bromo-2-methyl-4-phenyl-1-butene”, Martin J. Stoermer and John T. Pinhey, Molecules, 1998, 3, M58.

“Ethyl 3-hydroxy-3-methyl-5-phenylpentanoate”, Martin J. Stoermer and John T. Pinhey, Molecules, 1998, 3, M59.

“Ethyl 3-acetoxy-3-methyl-5-phenylpentanoate”, Martin J. Stoermer and John T. Pinhey, Molecules, 1998, 3, M60.

“3-Hydroxy-3-methyl-5-phenylpentanoic acid”, Martin J. Stoermer and John T. Pinhey, Molecules, 1998, 3, M61.

“Ethyl (E)-2-methyl-5-phenyl-2-pentenoate”, Martin J. Stoermer and John T. Pinhey, Molecules, 1998, 3, M62.

“Ethyl (Z)-2-methyl-5-phenyl-2-pentenoate”, Martin J. Stoermer and John T. Pinhey, Molecules, 1998, 3, M63.

“(E)-2-Methyl-5-phenyl-2-pentenoic acid”, Martin J. Stoermer and John T. Pinhey, Molecules, 1998, 3, M64.

“2,3-Dibromo-2-methyl-5-phenylpentanoic acid”, Martin J. Stoermer and John T. Pinhey, Molecules, 1998, 3, M65.

“(Z)-2-Bromo-5-phenyl-2-pentene”, Martin J. Stoermer and John T. Pinhey, Molecules, 1998, 3, M66.

“Tributyl-[(Z)-5-phenyl-2-penten-2-yl]stannane”, Martin J. Stoermer and John T. Pinhey, Molecules, 1998, 3, M67.

“[(Z)-5-Phenyl-2-penten-2-yl]mercury bromide”, Martin J. Stoermer and John T. Pinhey, Molecules, 1998, 3, M68.

“[(Z)-5-Phenyl-2-penten-2-yl]mercury acetate”, Martin J. Stoermer and John T. Pinhey, Molecules, 1998, 3, M69.

“bis-[(Z)-5-Phenyl-2-penten-2-yl]mercury”, Martin J. Stoermer and John T. Pinhey, Molecules, 1998, 3, M70.

“Ethyl (E)-3-(2-methoxyphenyl)-2-butenoate”, Martin J. Stoermer and John T. Pinhey, Molecules, 1998, 3, M71.

“Ethyl (Z)-3-(2-methoxyphenyl)-2-butenoate”, Martin J. Stoermer and John T. Pinhey, Molecules, 1998, 3, M72.

“(E)-3-(2-Methoxyphenyl)-2-butenoic acid”, Martin J. Stoermer and John T. Pinhey, Molecules, 1998, 3, M73.

 

Work web pageGroup HomeIMB HomeUQ home

Last updated 12th March 2017

 

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s